Suggestions
David Liebowitz
Senior Vice President, Early-Stage Clinical Development
David Liebowitz is a seasoned pharmaceutical executive with extensive experience in clinical development, particularly in the areas of oncology, infectious diseases, and vaccine development. He currently serves as the Senior Vice President of Early-Stage Clinical Development at INOVIO Pharmaceuticals, Inc.12
Career Highlights
Dr. Liebowitz has over 27 years of industry experience in clinical and preclinical development.3 His expertise spans various therapeutic areas, including oncology, infectious diseases, vascular biology, inflammation, and metabolic disorders. He has worked with diverse therapeutic modalities, including proteins, small molecules, cellular therapeutics, and vaccines.2
Previous Positions::
- Senior Vice President, Clinical Development and Medical Affairs at Xencor
- Chief Medical Officer at DNAtrix
- Chief Medical Officer at Vaxart Inc.
- Chief Scientific and Medical Officer at Vivaldi Biosciences Inc.
- Executive Vice President of R&D and Chief Scientific Officer at Galileo Pharmaceuticals
- Director of Research at Amgen
- Senior Director of Research at Immunex1
Academic Background
Dr. Liebowitz has a strong academic foundation:
- BS and MS in Biology from Emory University
- MD with Honors from The University of Chicago Pritzker School of Medicine
- PhD in Molecular Genetics and Cell Biology from The University of Chicago Pritzker School of Medicine13
Notable Achievements
During his tenure at Vaxart, Inc., Dr. Liebowitz led the successful application and negotiation process for acquiring a BARDA contract and served as the Principal Investigator of the award. He was also an early recipient of a grant from the Bill and Melinda Gates Foundation.3
Dr. Liebowitz began his career in academia as an Assistant Professor of Medicine and Virology at the University of Chicago, where he also directed the Bone Marrow Transplantation Program.3
His extensive experience and expertise make him a valuable asset to INOVIO Pharmaceuticals in advancing their early-stage clinical development programs.
